维普中文期刊产品整合服务
309篇 您的检索式:作者名="GANE E"
    题名 作者 年代 出处 被引量
1A complete sequence and comparative analysis of a SARS-associated virus(Isolate BJ01)显示文摘The genome sequence of the Severe Acute Respiratory Syndrome (SARS)-associated virus provides essential information for the identification of pathogen(s), exploration of etiology and evolution, interpretation of transmission and pathogenesis, development of diagnostics, prevention by future vaccination, and treatment by developing new drugs. We report the complete genome sequence and comparative analysis of an isolate (BJ01) of the coronavirus that has been recognized as a pathogen for SARS. The genome is 29725 nt in size and has 11 ORFs (Open Reading Frames). It is composed of a stable region encoding an RNA-dependent RNA polymerase (composed of 2 ORFs) and a variable region representing 4 CDSs (coding sequences) for viral structural genes (the S, E, M, N proteins) and 5 PUPs (putative uncharacterized proteins). Its gene order is identical to that of other known coronaviruses. The sequence alignment with all known RNA viruses places this virus as a member in the family of Coronaviridae. Thirty putative substitutions have been identified by comparative analysis of the 5 SARS- associated virus genome sequences in GenBank. Fifteen of them lead to possible amino acid changes (non-synonymous mutations) in the proteins. Three amino acid changes, with predicted alteration of physical and chemical features, have been detected in the S protein that is postulated to beinvolved in the immunoreactions between the virus and its host. Two amino acid changes have been detected in the Mprotein, which could be related to viral envelope formation. Phylogenetic analysis suggests the possibility of non-human origin of the SARS-associated viruses but provides noevidence that they are man-made. Further efforts should focus on identifying the etiology of the SARS-associated virus and ruling out conclusively the existence of otherpossible SARS-related pathogen(s).QIN E'de ZHU Qingyu YU Man FAN Baochang CHANG Guohui SI Bingyin YANG Bao PENG Wenming JIANG Tao LIU Bohua DENG Yongqiang LIU Hong ZHANG Yu WANG Cui LI Yuquan GAN Yonghua LI Xiaoyu L Fushuang TAN Gang CAO Wuchun, YANG Ruifu Institute of Microbiology and Epidemiology, Chinese Academy of Military Medical Sciences, Beijing 100071, China WANG Jian, LI Wei, XU Zuyuan, LI Yan, WU Qingfa, LIN Wei, CHEN Weijun, TANG Lin, DENG Yajun, HAN Yujun, LI Changfeng, LEI Meng, LI Guoqing, LI Wenjie, L Hong, SHI Jianping, TONG Zongzhong, ZHANG Feng, LI Songgang, LIU Bin, LIU Siqi, DONG Wei, WANG Jun, Gane K-S Wong, YU Jun & YANG Huanming* Beijing Genomics Institute, Chinese Academy of Sciences, Beijing 101300 National Center for Genome Information, Beijing 101300, China 2003Chinese Science Bulletin2003,48,10:121
2Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study显示文摘Patrick Marcellin Edward Gane Maria Buti Nezam Afdhal William Sievert Ira M Jacobson Mary Kay Washington George Germanidis John F Flaherty Raul Aguilar Schall Jeffrey D Bornstein Kathryn M Kitrinos G Mani Subramanian John G McHutchison E Jenny Heathcote 2012The Lancet2012,,:14
32-Year GLOBE trial results:telbivudine is superior to lamivudine in patients with chronic hepatitis B显示文摘Liaw YF Gane E Leung N Gastroenterology0,,:2
4Telbivudine displays consistent an tiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: results from the globe study 显示文摘Thongsawat S LaiCL Gane E 2006J Hepatol2006,44,2:1
5All-oral sofosbu- virbased 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study显示文摘Gane E J Stedman CA Hyland RH 2013Hepatol2013,58,1:1
6Baseline characteris- tics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B 显示文摘Zeuzem S Gane E Liaw YF 2009J Hepatol2009,51,1:1
7Sorafenib in advanced hepatocellular carcinoma显示文摘Llovet J M Ricci S Mazzaferro V Hilgard P Gane E Blanc J F 2008N Engl J Med2008,359,:1
8Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study显示文摘Marcellin P Gane E Buti M 2013Lancet2013,381,9865:1
9Randomised trial of efficacy and safety of oral gancielovir in the prevention of cyto- megalovirus disease in liver-transplant recipients显示文摘Gane E Saliba F Valdecasas GJ 1997Lancet1997,350,9093:1
10Telbivudine Clobe trial:maximal early HBV suppression is predicitive of optimal two-year efficacy in nucleoside-treated hepatient 显示文摘DIBISCEGLIE A LAI CL GANE E 2006Hepatology2006,44,:1
11Two-year results from the globe trial in patients with hepatitis:greater clinical and antiviral efficacy for telbivudine(LdT) vs lamivudine显示文摘Lai CL Gane E Hsu C W 2006Hepatology2006,44,41:1
12NEPTUNE Study: On-treatment HBsAg level analysis confirms prediction of response observed in phase 3 study of peginterferon alfa-2a in HBeAg-positive patients 显示文摘Gane E Jia J Han K Tanwandee T Chuang WL Marcellin P Chan HL Piratvisuth T Wat C Martins E Liaw YF 2011J Hepatol2011,54,:1
13Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B显示文摘Zeuzem S Gane E Liaw YF 2009Hepatology2009,51,1:1
14Baseline characteristics and early on - treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B 显示文摘Zeuzem S Gane E Liaw YF 2009Hapato12009,51,1:1
15Pre-and postoperative immunonutrition in patients undergoing liver transplantation:a pilot study of safety and efficacy显示文摘PLANK L D MCCALL L J GANE E J 2005Clin Nutrition2005,4,24:1
16Four years efficacy and safety of tenofovir didoproxil fumarate (TDF) in asians with chronic hepa- titis B (CHB)显示文摘Gane E Lee SL Hethcote EJ 2010Hepatology2010,52,4:1
17Two year results from the GLOBE trail in patients with hepatitis B: greater chnical and antiviral efficacy for telbivudine vs lamivudine 显示文摘Lai CL Gane E Hsu CW 2006Hepatolo- gy2006,44,41:1
18Regression of cirrhosisduring treatment with tenofovir disoproxil fμmarate for chronichepatitis B:a5-year open-label follow-up study显示文摘Marcellin P Gane E Buti M 2013Lancet2013,381,9865:1
19The oral toll-like receptor-7 ago- nist GS-9620 in patients with chronic hepatitis B virus infection 显示文摘Gane E J Lim YS Gordon SC 2015J Hepatol2015,63,2:1
202-Year GLOBE trial results:telbivudine Is superior to lamivudine in patients with chronic hepatitis B显示文摘Liaw YF Gane E Leung N 2009Gastroenterology2009,136,2:1
返回顶部 每页显示:
共16页 首页 上一页 第1页 下一页 末页 /16 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费